Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 50
2006 189
2007 203
2008 255
2009 253
2010 311
2011 384
2012 426
2013 431
2014 393
2015 385
2016 280
2017 282
2018 264
2019 166
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

3,708 results
Results by year
Filters applied: . Clear all
Page 1
AKT/PKB Signaling: Navigating the Network.
Manning BD, Toker A. Manning BD, et al. Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001. Cell. 2017. PMID: 28431241 Free PMC article. Review.
AKT as a Therapeutic Target for Cancer.
Song M, Bode AM, Dong Z, Lee MH. Song M, et al. Cancer Res. 2019 Mar 15;79(6):1019-1031. doi: 10.1158/0008-5472.CAN-18-2738. Epub 2019 Feb 26. Cancer Res. 2019. PMID: 30808672 Free article. Review.
Maximising the potential of AKT inhibitors as anti-cancer treatments.
Brown JS, Banerji U. Brown JS, et al. Pharmacol Ther. 2017 Apr;172:101-115. doi: 10.1016/j.pharmthera.2016.12.001. Epub 2016 Dec 3. Pharmacol Ther. 2017. PMID: 27919797 Free PMC article. Review.
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
O'Donnell JS, Massi D, Teng MWL, Mandala M. O'Donnell JS, et al. Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Semin Cancer Biol. 2018. PMID: 28467889 Review.
Akt in cancer: Mediator and more.
Revathidevi S, Munirajan AK. Revathidevi S, et al. Semin Cancer Biol. 2019 Dec;59:80-91. doi: 10.1016/j.semcancer.2019.06.002. Epub 2019 Jun 4. Semin Cancer Biol. 2019. PMID: 31173856 Review.
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N. Bertacchini J, et al. Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25. Cell Mol Life Sci. 2015. PMID: 25712020 Review.
Targeting AKT for cancer therapy.
Shariati M, Meric-Bernstam F. Shariati M, et al. Expert Opin Investig Drugs. 2019 Nov;28(11):977-988. doi: 10.1080/13543784.2019.1676726. Epub 2019 Oct 12. Expert Opin Investig Drugs. 2019. PMID: 31594388 Review.
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A. Saura C, et al. Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21. Cancer Discov. 2017. PMID: 27872130 Free PMC article. Clinical Trial.
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
LoRusso PM. LoRusso PM. J Clin Oncol. 2016 Nov 1;34(31):3803-3815. doi: 10.1200/JCO.2014.59.0018. Epub 2016 Sep 30. J Clin Oncol. 2016. PMID: 27621407 Free PMC article. Review.
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
Barra F, Evangelisti G, Ferro Desideri L, Di Domenico S, Ferraioli D, Vellone VG, De Cian F, Ferrero S. Barra F, et al. Expert Opin Investig Drugs. 2019 Feb;28(2):131-142. doi: 10.1080/13543784.2018.1558202. Epub 2018 Dec 21. Expert Opin Investig Drugs. 2019. PMID: 30574817 Review.
3,708 results
Jump to page
Feedback